David Chow

ORCID: 0000-0001-9719-2261
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer-related Molecular Pathways
  • Microtubule and mitosis dynamics
  • RNA and protein synthesis mechanisms
  • Ubiquitin and proteasome pathways
  • Plant-Microbe Interactions and Immunity
  • Chemical Synthesis and Analysis
  • Peptidase Inhibition and Analysis
  • Glycosylation and Glycoproteins Research
  • Click Chemistry and Applications
  • Polyamine Metabolism and Applications
  • Cancer-related gene regulation
  • HIV/AIDS drug development and treatment
  • Bacteriophages and microbial interactions
  • Cell death mechanisms and regulation
  • Metabolism and Genetic Disorders
  • Arsenic contamination and mitigation
  • Plant Pathogenic Bacteria Studies
  • Cancer therapeutics and mechanisms
  • Natural Compounds in Disease Treatment
  • RNA modifications and cancer
  • Protein Hydrolysis and Bioactive Peptides
  • Photosynthetic Processes and Mechanisms
  • Sphingolipid Metabolism and Signaling
  • Cancer Cells and Metastasis
  • Bacterial Genetics and Biotechnology

University of California, San Francisco
2019-2020

University of California, Irvine
2020

Amgen (United States)
2014

Academia Sinica
2000-2003

University of British Columbia
1994-1997

University of Guelph
1997

Georgetown University
1992

University of Washington
1992

We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor MDM2-p53 interaction. Continued research investigation N-alkyl substituent this series, focused in particular on previously underutilized interaction shallow cleft MDM2 surface, led to one-carbon tethered sulfone which gave rise substantial improvements biochemical cellular potency. Further produced AMG 232 (2), is currently being evaluated human clinical trials for treatment cancer. Compound 2...

10.1021/jm401753e article EN Journal of Medicinal Chemistry 2014-01-23

Previously we reported the purification of heparin-binding growth factor pleiotrophin (PTN) from supernatants human breast cancer cell line MDA-MB-231. To investigate further biological activities PTN and its potential role in cancer, cloned a cDNA expressed gene kidney adrenal carcinoma (SW-13). The harvested cells transfected with contained specific protein an apparent molecular mass 18 kDa. These stimulated proliferation endothelial as well anchorage-independent SW-13 normal rat...

10.1016/s0021-9258(18)35692-8 article EN cc-by Journal of Biological Chemistry 1992-12-01

Structure-based rational design led to the discovery of novel inhibitors MDM2–p53 protein–protein interaction. The affinity these compounds for MDM2 was improved through conformational control both piperidinone ring and appended N-alkyl substituent. Optimization afforded 29 (AM-8553), a potent selective inhibitor with excellent pharmacokinetic properties in vivo efficacy.

10.1021/jm300354j article EN Journal of Medicinal Chemistry 2012-04-23

We previously reported the discovery of AMG 232, a highly potent and selective piperidinone inhibitor MDM2–p53 interaction. Our continued search for diverse analogues led to novel morpholinone MDM2 inhibitors. This change core has significant impact on both potency metabolic stability compared series. Within this series, AM-8735 emerged as an with remarkable biochemical (HTRF IC50 = 0.4 nM) cellular (SJSA-1 EdU 25 nM), well pharmacokinetic properties. Compound 4 also shows excellent...

10.1021/jm401767k article EN Journal of Medicinal Chemistry 2014-02-18

Structural analysis of both the MDM2-p53 protein-protein interaction and several small molecules bound to MDM2 led design synthesis tetrasubstituted morpholinone 10, an inhibitor with a biochemical IC50 1.0 μM. The cocrystal structure 10 inspired two independent optimization strategies resulted in discovery morpholinones 16 27 possessing distinct binding modes. Both analogues were potent inhibitors cellular assays, (IC50 = 0.10 μM) also displayed suitable PK profile for vivo animal...

10.1021/jm400293z article EN Journal of Medicinal Chemistry 2013-04-18

We previously reported the discovery of potent and selective morpholinone piperidinone inhibitors MDM2-p53 interaction. These have in common a carboxylic acid moiety that engages an electrostatic interaction with MDM2-His96. Our continued search for diverse led to novel replacements these acids uncovering new interactions MDM2 protein. In particular, using pyridine or thiazole as isosteres resulted very analogues. From these, AM-6761 (4) emerged inhibitor remarkable biochemical (HTRF IC50 =...

10.1021/jm401911v article EN Journal of Medicinal Chemistry 2014-03-06

The wbp gene cluster, encoding the B-band lipopolysaccharide O antigen of Pseudomonas aeruginosa serotype O5 strain PAO1, was previously shown to contain a wzy (rfc) O-antigen polymerase. This study describes molecular characterization corresponding wzz (rol) gene, responsible for modulating chain length. P. Wzz has 19 20% amino acid identity with Escherichia coli, Salmonella enterica, and Shigella flexneri. Knockout mutations in serotypes O16 (which an structurally related that O5) yielded...

10.1128/jb.179.5.1482-1489.1997 article EN Journal of Bacteriology 1997-03-01

Continued optimization of the N-substituent in piperidinone series provided potent piperidinone–pyridine inhibitors 6, 7, 14, and 15 with improved pharmacokinetic properties rats. Reducing structure complexity N-alkyl substituent led to discovery 23, a simplified inhibitor MDM2. Compound 23 exhibits excellent substantial vivo antitumor activity SJSA-1 osteosarcoma xenograft mouse model.

10.1021/ml500142b article EN ACS Medicinal Chemistry Letters 2014-06-30

Targeting the inability of cancerous cells to adapt metabolic stress is a promising alternative conventional cancer chemotherapy. FTY720 (Gilenya), an FDA-approved drug for treatment multiple sclerosis, has recently been shown inhibit progression through down-regulation essential nutrient transport proteins, selectively starving death. However, clinical use therapy prohibited because its capability inducing immunosuppression (lymphopenia) and bradycardia when phosphorylated upon...

10.1021/acs.bioconjchem.9b00822 article EN Bioconjugate Chemistry 2020-01-27

In vitro drug metabolism studies during the early discovery stage are becoming increasingly important. With increasing demand for high throughput and quick turnaround time in studies, however, careful examination of results proper design experiments still crucial. this communication, we report identification mechanism formation a novel metabonate from incubations diamine-containing compound with liver microsomes. The appeared to be major product, its was NADPH- microsomal protein-dependent....

10.1124/dmd.105.008367 article EN Drug Metabolism and Disposition 2006-03-22

A proteinase secreted by the sapstaining fungus Ophiostoma piceae is thought to be necessary for primary retrieval of nitrogen from wood proteins. By using mass spectrometry (MS) techniques, we have established cleavage specificity this subtilisin-like serine proteinase. This work demonstrated potential MS in determining specificities newly isolated proteinases a relatively short time frame, and determined that O. showed substrate similar K. Primary insulin B-chain occurred between Leu15...

10.1016/0014-5793(95)01107-p article EN FEBS Letters 1995-10-30

Natural products serve as chemical blueprints for the majority of classes antibiotics in our clinical arsenal. The evolutionary process by which these molecules arise is inherently accompanied co-evolution resistance mechanisms that shorten lifetime any given class. Virginiamycin acetyltransferases (Vats) are proteins provide protection against streptogramins, potent Gram-positive inhibit bacterial ribosome. Due to challenge selectively modifying chemically complex, 23-membered macrocyclic...

10.26434/chemrxiv.8346107.v2 preprint EN cc-by-nc-nd 2019-07-01
Eugene M. Barnes Patricia A. Calkin Satoshi Kuroda Shigemi Norioka Masanori Mitta and 95 more Ikunoshin Kato Fumio Sakiyama Heinz Nika David Chow Daniel Heß Edward J. Bures Hamish Morrison Ruedi Aebersold G. Marius Clore Angela M. Gronenborn Bengt Persson Patrick Argos Peter James Andrew C. Cannons Larry P. Solomonson Kenneth E. Dombrowski W. E. Moddeman Stephen E. Wright Winona C. Barker David G. George Subhendra N. Mattagajasingh Hara P. Misra Shuan Shian Huang Jung San Huang Y. C. Lee Wolfgang Fischer A. Grey Craig Philip N. McFadden Jonathan A. Lindquist Michael Bartlet‐Jones W. Jeffery Henrik F. Hansen Darryl Pappin Tomas Bergman Lars Hjelmqvist Mats Estonius Hans Jörnvall Donna S. Dorow Harald Tschesche Vera Knäuper T. Kleine P. Reinemer S. Schnierer Frank Grams Wolfram Bode Christopher Southan Kenneth Fantom Patric Lavery J. B. C. Findlay D. Akrigg Teresa K. Attwood Marcus Beck A. J. Bleasby A.C.T. North David Parry-Smith David N. Perkins Alastair Aitken Y. Patel Hélène Martin David R. H. Jones K. Robinson J. Madrazo Steven Howell Ruedi Aebersold Daniel Heß Tom Yungwirth Michael Affolter Lawrence N. Amankwa Daniel Heß Ruedi Aebersold Harold A. Scheraga Chao Yang Natalia V. Valentinova Manlan Yang Zi -Wei Gu Antonio M. Gotto Norman J. Dovic̀hi Karen C. Waldron Min Chen Ian D. Ireland Akira Omori Sachiyo Yoshida Johann Schaller Stephan Lengweiler Egon E. Rickli José Bubis Julio Ortiz Carolina Möller Enrique J. Millán Victoria L. Boyd MeriLisa Bozzini Jindong Zhao Robert J. DeFranco Pau -Miau Yuan G. Marc Loudon

10.1007/bf01898855 article EN Journal of Protein Chemistry 1994-07-01
Coming Soon ...